We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 21, 2021

The Effect of Methotrexate and Targeted Immunosuppression on Immune Responses to the COVID-19 Vaccine BNT162b2

The Lancet. Rheumatology

 

Additional Info

The Lancet. Rheumatology
The Effect of Methotrexate and Targeted Immunosuppression on Humoral and Cellular Immune Responses to the COVID-19 Vaccine BNT162b2: A Cohort Study
Lancet Rheumatol 2021 Jul 08;[EPub Ahead of Print], SK Mahil, K Bechman, A Raharja, C Domingo-Vila, D Baudry, MA Brown, AP Cope, T Dasandi, C Graham, T Lechmere, MH Malim, F Meynell, E Pollock, J Seow, K Sychowska, JN Barker, S Norton, JB Galloway, KJ Doores, TIM Tree, CH Smith

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading